Analysts have been eager to weigh in on the Healthcare sector with new ratings on Springworks Therapeutics (SWTX – Research Report) and Becton Dickinson (BDX – Research Report).
Becton Dickinson (BDX)
TD Cowen analyst Josh Jennings maintained a Hold rating on Becton Dickinson on May 2 and set a price target of $271.00. The company’s shares closed last Friday at $234.68, close to its 52-week low of $229.40.
According to TipRanks.com, Jennings is a 4-star analyst with an average return of
Becton Dickinson has an analyst consensus of Moderate Buy, with a price target consensus of $280.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SWTX:
- 3 Best Stocks to Buy Now, 5/3/2024, According to Top Analysts
- SpringWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.18)
- SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
- SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
